Answer:
8.66%
Explanation:
The calculation for the real rate of return is displayed below:
Real rate of return = {(1 + nominal rate of return) ÷ (1 + inflation rate)} - 1
= {(1 + 11.65%) ÷ (1 + 2.75%)} - 1
= {(1.1165) ÷ (1.0275)} - 1
= 1.086 - 1
= 0.0866 or 8.66%
By applying the formula where the numerator is the nominal rate of return and the denominator is the inflation rate
Answer:
$73.47
Explanation:
2.87 es el dividendo actual pagado (D0)
Utiliza eso para calcular los dividendos para los próximos 5 años;
D1 = D0(1+g); donde g es la tasa de crecimiento
D1 = 2.87(1.08) = 3.0996
D2 = 3.0996(1.08) = 3.3476
D3 = 3.3476(1.08) = 3.6154
D4 = 3.6154(1.08) = 3.9046
D5 = 3.9046(1.08) = 4.2170
Luego, calcula los flujos de efectivo terminales;
D6 (año 2024) = 4.2170 (1.03) = 4.3435
Calcula el valor presente de todos los dividendos utilizando una tasa de descuento del 8% con la fórmula; PV = FV/
PV(D1) = 2.87
PV(D2) = 2.87
PV(D3) = 2.87
PV(D4) = 2.87
PV(D5) = 2.87
PV del valor terminal; PV(D6 en adelante) = 
= 59.1223
Suma los PV para hallar el valor por acción;
$2.87 +$2.87 +$2.87 +$2.87 +$2.87+ $59.1223 = $73.47
Part a. Produce the goods in-house and allow international sales managers to oversee marketing.
Advantages include:
- Complete authority over production processes.
- Simplicity in strategizing and scaling manufacturing.
- Enhanced control over human resources.
- Increased comprehension of European markets by foreign sales agents.
- Reduced exit costs in case of product failure.
Disadvantages consist of:
- Limited knowledge regarding pharmaceutical protocols in Europe.
- Risks to the brand's reputation if not correctly managed by foreign agents.
- Extra expenses in product delivery.
Part b. Produce the items in-house and establish a wholly-owned entity in Europe for marketing.
Pros encompass:
- Full oversight of manufacturing operations.
- Ease in creating strategies and ramping up production.
- Better human resource oversight.
- Protection of brand integrity since marketing is managed internally.
Cons include:
- Increased resource allocation for marketing.
- Insufficient information about pharmaceutical standards in Europe.
- Extra delivery costs.
Part c. Form a strategic partnership with a significant European pharmaceutical entity to manufacture products via a 50/50 joint venture for marketing.
Pros involve:
- Risk-sharing among the enterprises.
- No additional costs for delivery.
- Valuable insights into European regulations and marketing.
Cons involve:
- Diminished control over manufacturing.
- Share profits among partners.
- Moderate exit costs involved.
- Possible brand image damage due to the additional firm.
YTM is calculated to be 4.795%. The formula for yield to maturity (YTM) is provided as follows: YTM = [C + (F - P)/N] / [(F + P)/2], where C represents the coupon payment, F symbolizes the bond's face value, P indicates the bond's price, and N denotes the time to maturity. In our scenario, since payments are semi-annual, we have C = 2.7% x 1000 = $27, F = $1000, P = 106% x $1000 = $1060, and N = (15 - 2) x 2 = 26. Therefore, YTM = [$27 + ($1000 - $1060) / 26] / [($1000 + $1060) / 2] = $24.692 / $1030 = 2.3973%. When adjusted to a yearly basis, it equates to 2.3973% x 2 = 4.795%.
Answer: Apportionment
Explanation: Apportionment, also referred to as analogous estimating, is utilized when projects closely align with previous ones concerning features and costs. This allows for rapid estimation regarding project duration, cost, and features with minimal effort, accuracy, and reliance on historical data. The apportionment methodology is common in fairly standard projects with limited variation or customization.
